Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma-Reference-Cited by-同舟云学术

Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma

Published:2020-06 Issue:6 Volume:31 Page:780-788
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Moreno V.,Sepulveda J.M.,Vieito M.,Hernández-Guerrero T.,Doger B.,Saavedra O.,Ferrero O.,Sarmiento R.,Arias M.,De Alvaro J.,Di Martino J.,Zuraek M.,Sanchez-Pérez T.,Aronchik I.,Filvaroff E.H.,Lamba M.,Hanna B.,Nikolova Z.,Braña I.

Funder

Celgene

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference39 articles.

1. Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence;Chaidos;Ther Adv Hematol,2015

2. BET domain co-regulators in obesity, inflammation and cancer;Belkina;Nat Rev Cancer,2012

3. Targeting epigenetic readers in cancer;Dawson;N Engl J Med,2012

4. BET inhibitors: a novel epigenetic approach;Doroshow;Ann Oncol,2017

5. The mechanisms behind the therapeutic activity of BET bromodomain inhibition;Shi;Mol Cell,2014

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BET inhibition revealed varying MYC addiction mechanisms independent of gene alterations in aggressive B-cell lymphomas.;2024-07-22

2. Targeting BRD4: Potential therapeutic strategy for head and neck squamous cell carcinoma (Review);Oncology Reports;2024-04-12

3. The Non-hodgkin Lymphoma Treatment and Side Effects: A Systematic Review and Meta-analysis;Recent Patents on Anti-Cancer Drug Discovery;2024-02

4. Cancer epigenetics: from laboratory studies and clinical trials to precision medicine;Cell Death Discovery;2024-01-15

5. The bromodomain acyl-lysine readers in human health and disease;Chromatin Readers in Health and Disease;2024